Beginning with the observation that CtBP could act as a metabolic sensor to control genome stability in breast cancer through the early onset gene BRCA1, one group at the National Cancer Institute has provided one of the first comprehensive genomic analyses of the interaction of CtBP with the human genome [185]. The gene discussed is BRCA1; the disease is breast cancer.